Long Term Follow-up of Remission Patients in Adult Acute Leukemia

Overview

Journal Klin Wochenschr

Specialty General Medicine

Date 1983 Oct 3

PMID 6580502

Authors

D Gerecke

M Kress

W D Hirschmann

Affiliations

Soon will be listed here.

Abstract

31 adults suffering from acute leukemia were followed for a period of more than 5 years after achieving complete remission. Maintenance chemotherapy consisted of antimetabolite treatment (mercaptopurine + methotrexate) as well as COAP reinduction every 3 months. Chemotherapy was stopped if the first complete remission lasted for 3 years ("long term remission"). This was the case in 8 out of 31 remission patients (26%). Analysis of hematological parameters at diagnose for long term remission patients revealed that the initial leukocyte count was of prognostic significance.

References

Urbanitz D, Buchner T, Kamanabroo D, Hiddemann W, Schulte H, van de Loo J . Intensified remission induction therapy for acute nonlymphocytic leukemia (ANLL). Treatment report on 60 patients. Blut. 1981; 43(2):129-33. DOI: 10.1007/BF00320474. View

Thomas E, Buckner C, Banaji M, Clift R, Fefer A, Flournoy N . One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977; 49(4):511-33. View

Whittaker J, Slater A . The immunotherapy of acute myelogenous leukaemia using intravenous BCG. Br J Haematol. 1977; 37(1):153-4. DOI: 10.1111/j.1365-2141.1977.tb08822.x. View

Vaughan W, Karp J, Burke P . Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia. Cancer. 1980; 45(5):859-65. DOI: 10.1002/1097-0142(19800301)45:5<859::aid-cncr2820450506>3.0.co;2-z. View

Hollard D, Sotto J, Berthier R, Leger J, Michallet M . High rate of long-term survivals in AML treated by chemotherapy and androgenotherapy: a pilot study. Cancer. 1980; 45(7):1540-8. DOI: 10.1002/1097-0142(19800401)45:7<1540::aid-cncr2820450705>3.0.co;2-#. View

Powles R, Russell J, Lister T, Oliver T, WHITEHOUSE J, Malpas J . Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer. 1977; 35(3):265-72. PMC: 2025283. DOI: 10.1038/bjc.1977.38. View

Benohr H, Reu G, Wilms K, Waller H . [Long-term survival of adults with acute leukemia [author's transl)]. Blut. 1980; 40(6):399-406. DOI: 10.1007/BF01029681. View

Bodey G, Freireich E, MONTO R, HEWLETT J . Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. Cancer Chemother Rep. 1969; 53(1):59-66. View

Gerecke D, Hirschmann W, Voigtmann R, Gross R . Remission induction and remission maintenance in adult acute nonlymphocytic leukemia employing a modified cytostatic (COAP) regimen. Blut. 1979; 39(1):39-45. DOI: 10.1007/BF01008073. View

10.

Simone J . Factors that influence haematological remission duration in acute lymphocytic leukaemia. Br J Haematol. 1976; 32(4):465-72. DOI: 10.1111/j.1365-2141.1976.tb00950.x. View

11.

Cutler S, Ederer F . Maximum utilization of the life table method in analyzing survival. J Chronic Dis. 1958; 8(6):699-712. DOI: 10.1016/0021-9681(58)90126-7. View

12.

Whitecar Jr J, Bodey G, Freireich E, McCredie K, Hart J . Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep. 1972; 56(4):543-50. View

13.

Blume K, Beutler E, Bross K, Chillar R, Ellington O, Fahey J . Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med. 1980; 302(19):1041-6. DOI: 10.1056/NEJM198005083021901. View

14.

Creasey W, PAPAC R, Markiw M, Calabresi P, WELCH A . Biochemical and pharmacological studies with 1-beta-D-arabinofuranosylcytosine in man. Biochem Pharmacol. 1966; 15(10):1417-28. DOI: 10.1016/0006-2952(66)90186-9. View

15.

Keating M, Smith T, Gehan E, McCredie K, Bodey G, Spitzer G . Factors related to length of complete remission in adult acute leukemia. Cancer. 1980; 45(8):2017-29. DOI: 10.1002/1097-0142(19800415)45:8<2017::aid-cncr2820450806>3.0.co;2-c. View